AdvanCell Raises $315M Series D to Advance Targeted Alpha Radiopharmaceuticals for Cancer
核心洞察
Sydney-based AdvanCell secured a $315.0M Series D round to advance its targeted alpha radiopharmaceutical therapies for cancer (搜索) and support their development and manufacturing.
The financing brings AdvanCell's total equity funding to $439.5M, with backing from Eli Lilly, Sanofi Ventures (搜索), Bain Capital Life Sciences (搜索), and other life science investors.
The round attracted a broad syndicate including Abingworth, Ally Bridge Group, Fidelity, T. Rowe Price, and Catalio Capital Management, underscoring investor conviction in radiopharmaceutical oncology.
AdvanCell, a Sydney-based biotechnology company developing targeted alpha radiopharmaceutical therapies for cancer (搜索), has raised a $315.0 million Series D funding round. The financing brings the company's total equity funding to $439.5 million and will support the development and manufacturing of its radiopharmaceutical pipeline, according to data from CrunchBase.
Founded by Andrew Adamovich in 2019, AdvanCell operates across the biotechnology, clinical trials, oncology, and pharmaceutical sectors. The company's focus on targeted alpha radiopharmaceuticals positions it within a growing area of oncology drug development that seeks to deliver potent radiation directly to cancer (搜索) cells.
Investor Syndicate
The Series D round drew participation from a broad and prominent group of life science and technology investors. Backers in the round include Abingworth, Ally Bridge Group, Alpha Wave Global, Bain Capital Life Sciences (搜索), Brandon Capital, Catalio Capital Management, Eli Lilly, Eventide, Fidelity, Morningside, Piper Sandler, Proto Axiom, Sanofi Ventures (搜索), SV Health Investors, SymBiosis, Tenmile, TIME BioVentures, T. Rowe Price, and Velosity Capital.
The company's existing investor base includes Eli Lilly, Alpha Wave Global, Catalio Capital Management, Bain Capital Life Sciences (搜索), and SV Health Investors, reflecting sustained support from strategic pharmaceutical and dedicated life science funds.
Strategic Significance
The participation of Eli Lilly and Sanofi Ventures (搜索) — the venture arms of two major pharmaceutical companies — signals strategic interest in AdvanCell's radiopharmaceutical platform. Targeted alpha therapy represents an emerging therapeutic modality in oncology, leveraging alpha-emitting isotopes to deliver localized, high-energy radiation to malignant cells while aiming to spare surrounding healthy tissue.
The $315.0 million raise places AdvanCell among the largest healthcare-focused funding rounds tracked in the July 2026 global startup funding landscape, a period characterized by accelerating convergence of artificial intelligence with sectors including healthcare and by investor conviction in deep tech and platform plays.